Safety of the Herpes Zoster Subunit Vaccine in Lupus

Official title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Non-inferiority Crossover Study Evaluating the Safety and Immunogenicity of the Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus

Overview

This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment. In addition, the investigators hypothesize that immunogenicity of the vaccine in SLE patients will be at least 50% of levels observed in healthy subjects from prior large clinical trials.

Interventions

• Biological Herpes Zoster Subunit (HZ/su) Vaccine
  Manufactured by GSK Biologicals SA. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.
• Biological Placebo
  Saline injection. Administered as two-time injection of 0.5 mL each at either weeks 0 and 8 or weeks 24 and 32.

Primary outcome measures

• Occurrence of either Moderate or Severe Lupus Flares within 24 Weeks of First Dosing with HZ/su Vaccine [Time frame: Up to Week 48]

Secondary outcome measures (8)

• Occurrence of either Moderate or Severe Lupus Flares at Week 8 [Time frame: Week 8]
• Occurrence of either Moderate or Severe Lupus Flares at Week 24 [Time frame: Week 24]
• Occurrence of Mild, Moderate, or Severe Lupus Flares within 24 Weeks of First Dosing with HZ/su Vaccine [Time frame: Up to Week 48]
• Occurrence of New or Worsening Disease Activity in Any Organ System as Identified by BILAG 2004 within 24 Weeks of First Dosing with HZ/su Vaccine [Time frame: Up to Week 48]
• Occurrence of Increase in PGA Score by More than 0.3 Points within 24 Weeks of First Dosing with HZ/su Vaccine [Time frame: Up to Week 48]
• Occurrence of Grade 3 or Higher Adverse Events as Per CTCAE or Solicited AIT within 24 Weeks of First Dosing with HZ/su Vaccine [Time frame: Up to Week 48]
• Levels of Serum Varicella-Zoster Virus Anti-Glycoprotein E Antibodies at 4 Weeks after Last Dose of HZ/su Vaccine [Time frame: 4 Weeks after Last Dose of HZ/su Vaccine (Week 12 for Vaccine, then Placebo Arm; Week 36 for Placebo, then Vaccine Arm)]
• Levels of Serum Varicella-Zoster Virus Anti-Glycoprotein E Antibodies at 24 Weeks after First Dose of HZ/su Vaccine [Time frame: 24 Weeks after First Dose of HZ/su vaccine (Week 24 for Vaccine, then Placebo Arm; Week 48 for Placebo, then Vaccine Arm)]

Eligibility criteria

Inclusion criteria

• Provision of informed consent prior to any study specific procedures
• Female or male ≥18 years of age at the time of signing the informed consent
• Meet the 2019 EULAR/ACR Classification Criteria for SLE
• Female subjects must use 1 effective method of avoiding pregnancy, from the time they sign consent until end of the study period unless the subject is surgically sterile (e.g., bilateral oophorectomy or complete hysterectomy), has a sterile male partner, is at least 1 year postmenopausal, or practices sustained abstinence consistent with the subject's customary lifestyle. Postmenopausal is defined as at least 1 year since last menses and the subject has an elevated follicle-stimulating hormone (FSH) level greater than the threshold laboratory value of post-menopausal women at screening.

Exclusion criteria

• Prior administration of the Herpes Zoster subunit vaccine (Shingrix) or the Varicella-Zoster virus vaccine live (Zostavax)
• Clinical HZ infection within 12 months prior to screening or during screening
• Hybrid SLEDAI >12 at screening visit
• Presence of a mild, moderate, or severe flare per the rSFI at time of screenin
• Increase in clinical SLEDAI parameters at time of enrollment relative to screening visit
• Any vaccine, including the final/booster dose of any SARS-CoV-2 vaccine, within six weeks enrollment
• Receipt of rituximab or cyclophosphamide within nine months of enrollment
• Participation in an interventional clinical trial of SLE or other therapeutics within six months of enrollment
• Moderate to severe infectious febrile illness or use of systemic antibiotics (antibacterial, antiviral, antifungal, or antiparasitic agent) within 4 weeks of enrollment
• Are pregnant, nursing, or planning a pregnancy while enrolled in the study
• Known primary or secondary immunodeficiency (malignancy, HIV, common variable immune deficiency) or medications used during cancer chemotherapy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Crossover

Masking

Double blind

Primary purpose

Treatment

Study locations

United States · 2 centers

• NYU Langone Health — New York
• Oklahoma Medical Research Foundation — Oklahoma City

Identifiers

NCT: NCT05559671 · 22-00922

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗